¿¬±¸°³¹ß

3

Clinical Study of EarlyTect¢ç Colon Cancer

¿¬¼¼ÀÇ·á¿ø ¼¼ºê¶õ½º º´¿ø ¹× üũ¾÷ ¼¾ÅÍ¿¡¼­ 585¸íÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ È®Áõ ÀÓ»ó ½ÃÇè¿¡¼­ ´ëÀå¾Ï Áø´Ü¿¡ ´ëÇÏ¿©
¹Î°¨µµ 90.2% (221/245), ƯÀ̵µ 90.2%¸¦ ³ªÅ¸³Â½À´Ï´Ù. ´ëÀå¾Ï Á¶±â´Ü°èÀÎ 0-2±â ´ëÀå¾Ï¿¡ ´ëÇØ¼­´Â 89.1% (114/128)ÀÇ ¹Î°¨µµ¸¦ º¸¿´½À´Ï´Ù. EarlyTect Colon Cancer °Ë»çÀÇ ¹Î°¨µµ´Â ´ëÀå¾Ï º´±âº°, Á¾¾ç À§Ä¡, ¼ºº° ¹× ³ªÀÌ¿¡ À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò½À´Ï´Ù. º» ÀÓ»ó °á°ú¸¦ ¹ÙÅÁÀ¸·Î Çѱ¹½ÄǰÀǾàǰ¾ÈÀüó 3µî±Þ ü¿ÜÁø´ÜÀÇ·á±â±â Çã°¡(Á¦Çã18-593È£) ½ÂÀÎ ¹× ÀÓ»ó°á°ú´Â Clinical Epigenetics (2019, 11:51)Áö¿¡ ÃâÆÇµÇ¾ú½À´Ï´Ù.
EarlyTect¢ç Colon Cancer
  • ¹Î°¨µµ

    Sensitivity
    90.2% Ç÷¯½º ¾ÆÀÌÄÜ
  • ƯÀ̵µ

    Specificity
    90.2%
(95% CI 85.8-93.6)

´ëÀå¾Ï º´±âº° ¹Î°¨µµ

  • Stage 0

    100%

    (n=3/3)
  • Stage¥°

    85.5%

    (n=47/55)
  • Stage¥±

    91.4%

    (n=64/70)
  • Stage¥²

    89.6%

    (n=86/96)
  • Stage ¥³

    100%

    (n=21/21)
Clinical Study of EarlyTect¢ç Bladder Cancer

Ãæ³²´ëÇб³º´¿ø, °Ç¾ç´ëÇб³º´¿ø ¹× ´ëÀüÄ«Å縯¼º¸ðº´¿ø¿¡¼­ ³²³à Ç÷´¢È¯ÀÚ 574¸íÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Å½»ö ÀÓ»ó ½ÃÇè¿¡¼­ ¹æ±¤¾Ï Áø´Ü¿¡ ´ëÇÏ¿© ¹Î°¨µµ 84.0%, ƯÀ̵µ 94.0%¸¦ ³ªÅ¸³Â½À´Ï´Ù. ¹æ±¤¾Ï Á¶±â´Ü°èÀÎ pTa±â ¹æ±¤¾Ï¿¡ ´ëÇØ¼­´Â 74.0%ÀÇ ¹Î°¨µµ¸¦ º¸¿´½À´Ï´Ù.

Clinical Study of EarlyTect¢ç Lung Cancer

Ä¥°î°æºÏ´ëÇб³º´¿ø¿¡¼­ 522¸íÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ È®Áõ ÀÓ»ó ½ÃÇè¿¡¼­ Æó¾Ï Áø´Ü¿¡ ´ëÇÏ¿© ¹Î°¨µµ 77.8%, ƯÀ̵µ 92.3%¸¦ ³ªÅ¸³Â½À´Ï´Ù. Á¶±â¾Ï (I-II)¿¡ ´ëÇÑ ¹Î°¨µµ´Â 62.2%¿´°í, º´±â, Èí¿¬·Â ±×¸®°í ¿¬·É¿¡ µû¸¥ ¹Î°¨µµ Â÷ÀÌ´Â ¾ø½À´Ï´Ù.